ProjectPhase I, open-label, dose-escalation study to investigate the safety of ISTH0036, a ‘next generation’…
Basic data
Title:
Phase I, open-label, dose-escalation study to investigate the safety of ISTH0036, a ‘next generation’ TGF-β2-selective antisense oligonucleotide, in subjects with primary open-angle glaucoma undergoing trabeculectomy
Duration:
21/04/2015 to 31/12/2018
Abstract / short description:
A phase I, open-label, dose-escalation study to investigate the safety of ISTH0036, a ‘next generation’ TGF-β2-selective
antisense oligonucleotide, in subjects with primary open-angle glaucoma undergoing trabeculectomy.
antisense oligonucleotide, in subjects with primary open-angle glaucoma undergoing trabeculectomy.
Keywords:
ISTH0036
Glaucoma
Ophthalmologie
Studie Trial
Involved staff
Managers
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
University Eye Hospital
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
München, Bayern, Germany